EBS FY 2019 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

FY 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.1B+41.4% YoY

Gross Profit

$483M43.7% margin

Operating Income

$114M10.3% margin

Net Income

$55M4.9% margin

EPS (Diluted)

$1.04

Cash Flow

Operating Cash Flow

$188M

Free Cash Flow

$101M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.2B

Stockholders' Equity

$1.1B

Cash & Equivalents

$168M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$782M	+41.4%
Gross Profit	$483M	$320M	+50.8%
Operating Income	$114M	$90M	+27.1%
Net Income	$55M	$63M	-13.1%